Brussels, 28/11/2008 (Agence Europe) - While refraining from seeking to call into question the intellectual property rights that the pharmaceutical industry needs to ensure a return on investment and finance research and innovation, on Friday 28 November European Competition Commissioner Neelie Kroes set out at considerable length practices used by companies to delay the entry of generic medicines on the markets of European Union member states. At a hearing in Brussels, the commissioner...